Improving compliance and persistence with bisphosphonate therapy for osteoporosis

American Journal of Medicine

Volumn 119, Issue 4 SUPPL. 1, 2006, Pages S18-S24

  Emkey, Ronald D ^a   Ettinger, Mark ^a,b  

^a RADIANT RESEARCH   (United States)

^b Regional Osteoporosis Center   (United States)

Author keywords

Bisphosphonates; Compliance; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; IBANDRONIC ACID; RALOXIFENE; VITAMIN D;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DRUG DOSE REGIMEN; FOOD AND DRUG ADMINISTRATION; FRACTURE; HEALTH CARE COST; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 33645073160     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.12.019     Document Type: Article

References (31)

1. S.H. Gehlbach, C. Bigelow, M. Heimisdottir, S. May, M. Walker, J.R. Kirkwood Recognition of vertebral fracture in a clinical setting Osteoporos Int 11 2000 577 582
2. J.T. Harrington, S.B. Broy, A.M. Derosa, A.A. Licata, D.A. Shewmon Hip fracture patients are not treated for osteoporosis a call to action Arthritis Rheum 47 2002 651 654
3. S.E. Andrade, S.R. Majumdar, K.A. Chan Low frequency of treatment of osteoporosis among postmenopausal women following a fracture Arch Intern Med 163 2003 2052 2057
4. P.J. Kroth, M.D. Murray, C.J. McDonald Undertreatment of osteoporosis in women, based on detection of vertebral compression fractures on chest radiography Am J Geriatr Pharmacother 2 2004 112 118
5. G.M. Kiebzak, G.A. Beinart, K. Perser, C.G. Ambrose, S.J. Siff, M.H. Heggeness Undertreatment of osteoporosis in men with hip fracture Arch Intern Med 162 2002 2217 2222
6. F. Hooven, S.H. Gehlbach, P. Pekow, E. Bertone, E. Benjamin Follow-up treatment for osteoporosis after fracture Osteoporos Int 16 2005 296 301
7. M. Gass, B. Dawson-Hughes Preventing osteoporotic fracture an overview Am J Med 119 4A 2006 3S 11S
8. C.A. Jackevicius, M. Mamdani, J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 2002 462 467
9. B. Bender, H. Milgrom, C. Rand Nonadherence in asthmatic patients is there a solution to the problem? Ann Allergy Asthma Immunol 79 1997 177 185
10. S.L. Becker, C.M. Dezii, B. Burtcel, H. Kawabata, S. Hodder Young HIV-infected adults are at greater risk for medication nonadherence MedGenMed 4 2002 21 [serial online]
11. E. Segal, A. Tamir, S. Ish-Shalom Compliance of osteoporotic patients with different treatment regimens Isr Med Assoc J 5 2003 859 862
12. R.A. Yood, S. Emani, J.I. Reed, B.E. Lewis, M. Charpentier, E. Lydick Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 2003 965 968
13. J.J. Caro, K.J. Ishak, K.F. Huybrechts, G. Raggio, C. Naujoks The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 2004 1003 1008
14. Siris E, Rosen CJ, Harris ST, Abbott TA III, Barr CE, Silverman SL. Adherence to bisphosphonate therapy: relationship to bone fractures at 24 months in women with post-menopausal osteoporosis. Presented at the National Osteoporosis Foundation 6th International Symposium on Osteoporosis; April 6-9, 2005; Washington, DC.
15. J.A. Clowes, N.F. Peel, R. Eastell The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis a randomized controlled trial J Clin Endocrinol Metab 89 2004 1117 1123
16. R. Emkey, P.D. Delmas, S. Goemaere Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients a retrospective, observational study Arthritis Rheum 48 2003 1102 1108
17. E.R. Cox, C. Jernigan, S.J. Coons, J.L. Draugalis Medicare beneficiaries' management of capped prescription benefits Med Care 39 2001 296 301
18. E.R. Cox, R.R. Henderson Prescription use behavior among Medicare beneficiaries with capped prescription benefits J Manag Care Pharm 8 2002 360 364
19. W.J. Strickland, D.L. Strickland Coping with the cost of care an exploratory study of lower income minorities in the rural South [abstract] Family Community Health 18 1995 51
20. Bigger co-payments lead to falls in compliance, new US survey finds [letter] Pharm J 270 2003 69
21. B. Hamilton, K. McCoy, H. Taggart Tolerability and compliance with risedronate in clinical practice Osteoporos Int 14 2003 259 262
22. A.J. Claxton, J. Cramer, C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
23. C.M. Dezii, H. Kawabata, M. Tran Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes South Med J 95 2002 68 71
24. M.P. Ettinger, R. Gallagher, M. Amonkar Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate Arthritis Rheum 15 suppl 2004 S513
25. Fosamax (alendronate sodium) tablet and oral solution [prescribing information] 2004 Merck & Co., Inc Whitehouse Station, NJ
26. Boniva (ibandronate sodium) tablets [prescribing information] 2005 Roche Laboratories Inc Nutley, NJ
27. Actonel (risedronate sodium tablets) [prescribing information] 2004 Aventis Pharmaceuticals, Inc Kansas City, MO
28. J.P. Brown, D.L. Kendler, M.R. McClung The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif Tissue Int 71 2002 103 111
29. T. Schnitzer, H.G. Bone, G. Crepaldi Alendronate Once-Weekly Study Group Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging (Milano) 12 2000 1 12
30. P.D. Miller, M.R. McClung, L. Macovei Monthly oral ibandronate therapy in postmenopausal osteoporosis 1-year results from the MOBILE study J Bone Miner Res 20 2005 1315 1322
31. Silverman S, Greenwald M, Hawker G, et al. Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE. Presented at the American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Scientific Meeting; November 15, 2005; San Diego, CA.